Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2002

Content (12 Articles)

Conference Report

Bilateral Synchronous Breast Cancer and HER-2/neu Overexpression

Malek Safa, Elyse E. Lower, P.O. Hasselgren, Eric S. Hungness, Paula Gazder, Bernard Aron, Elizabeth A. Shaughnessy, Rawia Yassin

Conference Report

Synergistic Interaction Between Vinorelbine and Gamma-Linolenic Acid in Breast Cancer Cells

Javier Abel Menéendez, Santiago Ropero, Maria del Mar Barbacid, Sagrario Montero, Montserrat Solanas, Eduard Escrich, Hernán Cortés-Funes, Ramon Colomer

Conference Report

True Positive Somatostatin Receptor Scintigraphy in Primary Breast Cancer Correlates with Expression of sst2A and sst5

Solveig Schulz, Thekla Helmholz, Johannes Schmitt, Kornelia Franke, Hans-Jüurgen Otto, Wolfgang Weise

Conference Report

Expression of Ets-related Transcription Factors and Matrix Metalloproteinase Genes in Human Breast Cancer Cells

Jane M. Barrett, Mark A. Puglia, Gurmit Singh, Richard G. Tozer

Conference Report

Long-Term Follow-Up of a Phase II Trial Studying a Weekly Doxorubicin-Based Multiple Drug Adjuvant Therapy for Stage II Node-Positive Carcinoma of the Breast

Gretchen G. Kimmick, Brent J. Shelton, L. Douglas Case, M. Robert Cooper, Hyman B. Muss

Conference Report

Hysteroscopic Assessment of Menopausal Breast-Cancer Patients Taking Tamoxifen; There is a Bias from the Mode of Endometrial Sampling in Estimating Endometrial Morbidity?

Giancarlo Garuti, Francesco Grossi, Fulvia Cellani, Giovanna Centinaio, Monica Colonnelli, Massimo Luerti

Conference Report

Nuclear Medicine Imaging For Prediction or Early Assessment of Response to Chemotherapy in Patients Suffering From Breast Carcinoma

Christophe van de Wiele, Rudi Dierckx, Francesco Scopinaro, Rikki Waterhouse, Alessio Annovazzi, Anna Kolindou, Alberto Signore

Authors Index

Author index, Volume 72

Volume Contents

Subject index, Volume 72

Instructions for Authors

Instructions for Authors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine